Xencor, Inc Payments to Acquire Marketable Securities
Xencor, Inc (XNCR) reported Payments to Acquire Marketable Securities of $72.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-05
- Xencor, Inc payments to acquire marketable securities for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Xencor, Inc payments to acquire marketable securities for the quarter ending 2026-03-31 was $72.68M, a 30.03% decline year-over-year.
- Xencor, Inc payments to acquire marketable securities for the quarter ending 2025-12-31 was $37.85M, a 30.18% decline year-over-year.
- Xencor, Inc payments to acquire marketable securities for the quarter ending 2025-09-30 was $84.23M, a 70.10% decline year-over-year.
- Xencor, Inc payments to acquire marketable securities for fiscal 2025 was $298.89M, a 49.77% decline from fiscal 2024.
- Xencor, Inc payments to acquire marketable securities for fiscal 2024 was $595.05M, a 23.99% decline from fiscal 2023.
- Xencor, Inc payments to acquire marketable securities for fiscal 2023 was $782.90M, a 101.82% increase from fiscal 2022.
- Xencor, Inc payments to acquire marketable securities for fiscal 2022 was $387.93M, a 23.88% decline from fiscal 2021.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $72.68M 10-Q · filed 2026-08-05 | $110.53M derived: sum of 3 quarters · filed 2026-08-05 | $194.76M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $72.68M 10-Q · filed 2026-05-06 | $110.53M derived: sum of 2 quarters · filed 2026-05-06 | $194.76M derived: sum of 3 quarters · filed 2026-05-06 | $267.70M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $37.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $122.08M derived: sum of 2 quarters · filed 2026-02-25 | $195.02M derived: sum of 3 quarters · filed 2026-08-05 | $298.89M 10-K · filed 2026-02-25 |
| 2025-09-30 | $84.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $157.17M derived: sum of 2 quarters · filed 2026-08-05 | $261.05M 10-Q · filed 2025-11-05 | $315.25M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $72.94M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $176.81M 10-Q · filed 2026-08-05 | $231.02M derived: sum of 3 quarters · filed 2026-08-05 | $512.73M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $103.87M 10-Q · filed 2026-05-06 | $158.08M derived: sum of 2 quarters · filed 2026-05-06 | $439.80M derived: sum of 3 quarters · filed 2026-05-06 | $562.39M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $54.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $335.92M derived: sum of 2 quarters · filed 2026-02-25 | $458.52M derived: sum of 3 quarters · filed 2026-02-25 | $595.05M 10-K · filed 2026-02-25 |
| 2024-09-30 | $281.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $404.31M derived: sum of 2 quarters · filed 2025-11-05 | $540.84M 10-Q · filed 2025-11-05 | $879.27M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $122.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $259.13M 10-Q · filed 2025-08-06 | $597.55M derived: sum of 3 quarters · filed 2026-02-25 | $765.32M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $136.53M 10-Q · filed 2025-05-07 | $474.96M derived: sum of 2 quarters · filed 2026-02-25 | $642.72M derived: sum of 3 quarters · filed 2026-02-25 | $824.21M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $338.43M derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-02-25 | $506.19M derived: sum of 2 quarters · filed 2026-02-25 | $687.68M derived: sum of 3 quarters · filed 2026-02-25 | $782.90M 10-K · filed 2026-02-25 |
| 2023-09-30 | $167.76M derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2025-02-24 | $349.25M derived: sum of 2 quarters · filed 2025-02-24 | $444.48M 10-Q/A · filed 2025-02-24 | $515.35M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $181.49M derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2025-02-24 | $276.71M 10-Q/A · filed 2025-02-24 | $347.58M derived: sum of 3 quarters · filed 2025-02-27 | $458.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $95.23M 10-Q/A · filed 2025-02-24 | $166.10M derived: sum of 2 quarters · filed 2025-02-27 | $277.01M derived: sum of 3 quarters · filed 2025-02-27 | $394.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $70.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $181.78M derived: sum of 2 quarters · filed 2025-02-27 | $299.16M derived: sum of 3 quarters · filed 2025-02-27 | $387.93M 10-K · filed 2025-02-27 |
| 2022-09-30 | $110.91M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $228.29M derived: sum of 2 quarters · filed 2023-11-08 | $317.06M 10-Q · filed 2023-11-08 | $438.83M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-06-30 | $117.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $206.15M 10-Q · filed 2023-08-03 | $327.92M derived: sum of 3 quarters · filed 2025-02-24 | $484.29M derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-03-31 | $88.76M 10-Q · filed 2023-05-08 | $210.53M derived: sum of 2 quarters · filed 2025-02-24 | $366.90M derived: sum of 3 quarters · filed 2025-02-24 | $514.22M derived: sum of 4 quarters · filed 2025-02-24 |
| 2021-12-31 | $121.77M derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-02-24 | $278.14M derived: sum of 2 quarters · filed 2025-02-24 | $425.46M derived: sum of 3 quarters · filed 2025-02-24 | $509.60M 10-K/A · filed 2025-02-24 |
| 2021-09-30 | $156.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $303.69M derived: sum of 2 quarters · filed 2022-11-07 | $387.83M 10-Q · filed 2022-11-07 | $554.17M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $147.32M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $231.46M 10-Q · filed 2022-08-03 | $397.81M derived: sum of 3 quarters · filed 2023-02-27 | $572.80M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $84.14M 10-Q · filed 2022-05-05 | $250.49M derived: sum of 2 quarters · filed 2023-02-27 | $425.48M derived: sum of 3 quarters · filed 2023-02-27 | $585.32M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $166.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $341.34M derived: sum of 2 quarters · filed 2023-02-27 | $501.18M derived: sum of 3 quarters · filed 2023-02-27 | $643.66M 10-K · filed 2023-02-27 |
| 2020-09-30 | $174.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $334.83M derived: sum of 2 quarters · filed 2021-11-08 | $477.31M 10-Q · filed 2021-11-08 | $621.99M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $159.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $302.32M 10-Q · filed 2021-08-04 | $447.00M derived: sum of 3 quarters · filed 2022-02-24 | $554.67M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $142.48M 10-Q · filed 2021-05-05 | $287.16M derived: sum of 2 quarters · filed 2022-02-24 | $394.83M derived: sum of 3 quarters · filed 2022-02-24 | $589.48M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $144.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $252.36M derived: sum of 2 quarters · filed 2022-02-24 | $447.00M derived: sum of 3 quarters · filed 2022-02-24 | $496.86M 10-K · filed 2022-02-24 |
| 2019-09-30 | $107.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $302.32M derived: sum of 2 quarters · filed 2020-11-06 | $352.17M 10-Q · filed 2020-11-06 | $398.89M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-06-30 | $194.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $244.50M 10-Q · filed 2020-08-05 | $291.21M derived: sum of 3 quarters · filed 2021-02-24 | $336.53M derived: sum of 4 quarters · filed 2021-02-24 |
| 2019-03-31 | $49.86M 10-Q · filed 2020-05-08 | $96.57M derived: sum of 2 quarters · filed 2021-02-24 | $141.89M derived: sum of 3 quarters · filed 2021-02-24 | $396.00M derived: sum of 4 quarters · filed 2021-02-24 |
| 2018-12-31 | $46.71M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $92.03M derived: sum of 2 quarters · filed 2021-02-24 | $346.14M derived: sum of 3 quarters · filed 2021-02-24 | $377.84M 10-K · filed 2021-02-24 |
| 2018-09-30 | $45.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | $299.43M derived: sum of 2 quarters · filed 2019-11-05 | $331.13M 10-Q · filed 2019-11-05 | $358.45M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-30 | $254.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $285.81M 10-Q · filed 2019-08-07 | $313.13M derived: sum of 3 quarters · filed 2020-02-25 | $328.90M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-03-31 | $31.70M 10-Q · filed 2019-05-09 | $59.02M derived: sum of 2 quarters · filed 2020-02-25 | $74.79M derived: sum of 3 quarters · filed 2020-02-25 | $101.24M derived: sum of 4 quarters · filed 2020-02-25 |
| 2017-12-31 | $27.33M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $43.09M derived: sum of 2 quarters · filed 2020-02-25 | $69.54M derived: sum of 3 quarters · filed 2020-02-25 | $76.53M 10-K · filed 2020-02-25 |
| 2017-09-30 | $15.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-05 | $42.22M derived: sum of 2 quarters · filed 2018-11-05 | $49.20M 10-Q · filed 2018-11-05 | $163.21M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-06-30 | $26.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $33.44M 10-Q · filed 2018-08-07 | $147.44M derived: sum of 3 quarters · filed 2019-02-26 | $342.47M derived: sum of 4 quarters · filed 2019-02-26 |
| 2017-03-31 | $6.99M 10-Q · filed 2018-05-07 | $120.99M derived: sum of 2 quarters · filed 2019-02-26 | $316.01M derived: sum of 3 quarters · filed 2019-02-26 | $306.80M derived: sum of 4 quarters · filed 2019-02-26 |
| 2016-12-31 | $114.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $309.03M derived: sum of 2 quarters · filed 2019-02-26 | $299.81M derived: sum of 3 quarters · filed 2019-02-26 | $316.15M 10-K · filed 2019-02-26 |
| 2016-09-30 | $195.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $185.81M derived: sum of 2 quarters · filed 2017-11-08 | $202.15M 10-Q · filed 2017-11-08 | $249.46M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | -$9.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $7.12M 10-Q · filed 2017-08-07 | $54.43M derived: sum of 3 quarters · filed 2018-02-28 | $74.59M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $16.34M 10-Q · filed 2017-05-10 | $63.65M derived: sum of 2 quarters · filed 2018-02-28 | $83.81M derived: sum of 3 quarters · filed 2018-02-28 | $184.22M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $47.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $67.47M derived: sum of 2 quarters · filed 2018-02-28 | $167.88M derived: sum of 3 quarters · filed 2018-02-28 | $215.80M 10-K · filed 2018-02-28 |
| 2015-09-30 | $20.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | $120.58M derived: sum of 2 quarters · filed 2016-11-02 | $168.49M 10-Q · filed 2016-11-02 | |
| 2015-06-30 | $100.42M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $148.33M 10-Q · filed 2016-08-03 | ||
| 2015-03-31 | $47.91M 10-Q · filed 2016-05-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |